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 にど 
Abstract にな 
Clostridium difficile is an anaerobic, Gram positive and spore forming bacterium にに 
that is the leading worldwide infective cause of hospital-acquired and antibiotic-にぬ 
associated diarrhea. Several studies have reported associations between にね 
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 に
humoral immunity and the clinical course of C. difficile infection (CDI). Host にの 
humoral immune responses are determined using conventional enzyme-linked には 
immunosorbant assay (ELISA) techniques. Herein, we report the first use of a にば 
novel protein microarray assay to determine systemic IgG antibody responses にぱ 
against a panel of highly purified C. difficile-specific antigens, including native にひ 
toxins A and B (TcdA and TcdB), recombinant fragments of toxins A and B (TxA4 ぬど 
and TxB4), ribotype-specific surface layer proteins (SLPs; 001, 002, 027) and ぬな 
control proteins (tetanus and candida). Microarrays were probed with sera from a ぬに 
total of 327 individuals with CDI, cystic fibrosis without diarrhea, and healthy ぬぬ 
controls. For all antigens, precision profiles demonstrated <10% coefficient of ぬね 
variation (CV). Significant correlation was observed between microarray and ぬの 
ELISA in the quantification of anti-toxin A and -B IgG. These results indicate that ぬは 
microarray is a suitable assay for defining humoral immune responses to C. ぬば 
difficile protein antigens and may have potential advantages in throughput, ぬぱ 
convenience and cost.  ぬひ 
192 words ねど 
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Introduction ねに 
Clostridium difficile is the leading worldwide infective cause of hospital-acquired ねぬ 
and antibiotic-associated diarrhea, imposing a considerable financial burden on ねね 
health service providers in both Europe and the USA [1-3]. Infection causes a ねの 
spectrum of clinical presentations, ranging from an asymptomatic carrier state to ねは 
severe fulminant colitis and death [4]. Following successful treatment, an ねば 
 ぬ
estimated 20-30% of patients with primary C. difficile infection (CDI) develop ねぱ 
recurrence of symptoms, either caused by relapse of the original infection or ねひ 
reinfection with a new strain [5].  のど 
 のな 
This anaerobic and spore-forming bacterium exerts its major pathological effects のに 
through two pro-inflammatory and cytotoxic protein exotoxins, TcdA (toxin A) and のぬ 
TcdB (toxin B) [6]. Non-toxin virulence factors such as surface layer proteins のね 
(SLPs) and cell wall proteins (CWPs) have also been described, and may play a のの 
role in disease expression [7-9]. のは 
 のば 
The majority of healthy adults have detectable antibodies to C. difficile TcdA and のぱ 
TcdB in their serum that are thought to arise from colonization in infancy or from のひ 
repeated exposure to C. difficile in adulthood from the environment [10-11]. はど 
Several clinical studies suggest that adaptive humoral immune responses, in はな 
particular to TcdA and TcdB, may influence clinical outcomes of CDI [12]. Most はに 
notably, a landmark study in 2000 reported that a low IgG titre to TcdA, but not はぬ 
TcdB, at the time of infection is associated with development of symptomatic はね 
disease [13]. More recently, the same group demonstrated an association はの 
between median IgG titres to TcdA and 30-day all-cause mortality [14]. Several はは 
reports have also assessed antibody responses following infection and shown はば 
protection against recurrence associated with antibody responses to TcdA, TcdB はぱ 
and several non-toxin antigens (Cwp66, Cwp84, FliC, FliD and the surface layer はひ 
proteins) [15-18]. By contrast, other studies have reported that humoral immune ばど 
 ね
responses did not influence the clinical course of CDI [18-21].  These conflicting ばな 
reports may be attributed to heterogeneity in study design and subject ばに 
populations. Although the role of humoral immunity remains incompletely ばぬ 
understood, vaccination strategies using inactivated toxins or recombinant toxin ばね 
fragments are currently the subject of intense investigation [22-23]. More ばの 
recently, the possibility of adding other vaccine targets such as surface-ばは 
associated proteins and polysaccharides to toxin combinations is gaining traction, ばば 
and could be of added value in the prevention of C. difficile colonization and ばぱ 
disease transmission [22-23]. It is likely that the design of these next generation ばひ 
multicomponent vaccines targeting colonization, persistence and toxin production ぱど 
will stimulate the requirement for evaluating humoral immune responses to ぱな 
multiple antigens.  ぱに 
 ぱぬ 
The enzyme-linked immunosorbant assay (ELISA) is the traditional method of ぱね 
accurately quantifying antibodies with different specificities in epidemiologic ぱの 
research and vaccine development as well as in the diagnosis of allergies, ぱは 
autoimmune and infectious diseases. We and other groups [13, 15, 18-20] have ぱば 
independently developed and used a traditional standardized ELISA format for ぱぱ 
the purposes of determining human specific IgG responses against C. difficile ぱひ 
antigens (toxins). However, ELISA based tests can be time-consuming and ひど 
require large quantities of both sample and reagents, thus limiting their potential ひな 
for high-throughput use [23-24]. ELISA offers only monoplex data, or results of a ひに 
single protein per assay (typically TcdA, TcdB or SLPs) and from a single C. ひぬ 
 の
difficile strain. Additional concerns include the lack of a uniform standard for ひね 
calibration purposes and thus no generally accepted way of expressing ELISA ひの 
units, as well as poor consistency between protocols and reagents, including ひは 
notably the quality and source of antigens. Moreover, the linear region of the ひば 
dynamic range is highly platform dependent.  ひぱ 
Recently, protein microarrays, a miniaturized version of a sandwich ELISA, have ひひ 
evolved as a promising tool for quantifying specific antibodies directed against などど 
various microbial antigens in human sera, and may be an attractive alternative to などな 
conventional ELISA assays in determining antigen-specific antibody responses などに 
[25-31]. Microarray assays have potentially important advantages compared with などぬ 
standard ELISA formats. These include a much increased capacity for などね 
multiplexing detection of a range of specific antibodies due to the flexibility of などの 
array printing of multiple antigens per array over a single protein, vastly reduced などは 
requirements for antigens, serum and reagents, increased assay robustness due などば 
to increased technical replication within each assay, multiple internal quality などぱ 
control measures and improved quality control capabilities. The unique などひ 
capabilities of microarray including parallelism, high-throughput and ななど 
miniaturization are ideally suited to comprehensive investigation of the humoral ななな 
immune response to the entire proteome of an infectious agent consisting of ななに 
thousands of potential antigens, in a patient-specific manner [29]. Microarray ななぬ 
technology can also be applied to the development of improved serodiagnostic ななね 
tests, discovery of subunit vaccine antigen candidates, epidemiological research ななの 
 は
and vaccine development, in addition to providing novel insights into infectious ななは 
disease and the immune system [29].   ななば 
 ななぱ 
We have developed and validated a novel customized microarray platform that ななひ 
enables the simultaneous quantification of systemic IgG immune responses to a なにど 
7-plex panel of highly purified C. difficile-specific virulence factors, including なにな 
whole toxins A and B, recombinant fragments of toxin A (TxA4) and toxin B なにに 
(TxB4), type-specific surface layer proteins and suitable control proteins. We なにぬ 
compared the performance of the microarray technique with a conventional なにね 
ELISA using an established panel of sera. なにの 
 なには 
 なにば 
Materials and Methods なにぱ 
 なにひ 
Microbial proteins and serum samples なぬど 
Highly purified whole toxins A and B (toxinotype 0, strain VPI10463, ribotype 087) なぬな 
in addition to recombinant toxin fragments TxA4 and TxB4, (comprising central なぬに 
and receptor binding domains and both based on toxinotype 0 sequences), were なぬぬ 
obtained from Public Health England, UK (Dr Clifford Shone). Purified なぬね 
polymerase chain reaction (PCR) ribotype-specific native whole SLPs (001, 002, なぬの 
027) were provided by Dublin City University, Eire (Professor Christine Loscher). なぬは 
Positive controls incorporated on each plate included tetanus toxoid and lysates なぬば 
from Candida albicans containing the cytoplasm and cell wall.   なぬぱ 
 ば
Negative controls included spotted printing buffer (PBS Trehalose Tween) and no なぬひ 
serum (blank) on each array. なねど 
 なねな 
Banked sera from adult patients with CDI [n=150; median age 67 years (range なねに 
19-98 years], a group of patients with cystic fibrosis (CF) without diarrhea [n=17 なねぬ 
where 2 of these patients were found to be asymptomatic carriers; median age なねね 
28 (19-49 years)] and healthy controls [n=67; median age 36 years (22-65 なねの 
years)] were used to investigate the ability of the microarray assay to detect the なねは 
presence or absence of IgG directed against C. difficile microbial and control なねば 
antigens. Adult healthy donors were recruited from within the hospital and なねぱ 
University workforce setting. All the patients in the CDI group had diarrhea なねひ 
(defined as a change in bowel habit with 3 or more unformed stools per day for at なのど 
least 48 hours) and positive stool C. difficile toxin test. Asymptomatic carriers なのな 
were defined as those without diarrhea, but had a positive stool culture for C. なのに 
difficile. The diagnosis of CF had previously been made on the basis of a positive なのぬ 
sweat test and/or demonstration of 2 known CF mutations and typical clinical なのね 
features of disease (without a history of CDI). All subjects provided written なのの 
informed consent under approvals granted by the Nottingham Research Ethics なのは 
Committee. なのば 
 なのぱ 
Preparation and processing of arrayed antigens なのひ 
 なはど 
 ぱ
Microbial antigens were diluted to 200たg/ml in printing buffer (PBS Trehalose なはな 
Tween) in a 384-well plate (Genetix) and spotted in quadruplicate in a 16 x 16 なはに 
array format onto poly-L-Lysine-coated glass slides (Electron Microscopy なはぬ 
Sciences) using a Biorobotics MicroGridlI arrayer (Microgrid 610, Digilab, なはね 
Malborough, MA, USA) in addition to 15 human serial IgG dilutions (range 50 なはの 
たg/ml – 3.05 ng/ml) to create a calibration curve. The slides were blocked with なはは 
5% BSA diluted in PBS-Tween (PBST; PBS containing 0.05% Tween-20) wash なはば 
buffer for 1 hour at room temperature (RT) with shaking. After washing 5 times なはぱ 
for 3 minutes each with PBST, all slides were incubated with sera diluted 1:500 in なはひ 
antibody diluent (Dako) for 1 hour. Following washing, the slides were incubated なばど 
with biotinylated anti-human IgG (Vector Labs) diluted 1:20,000 in antibody なばな 
diluent for 1 hour. After further washing, slides were incubated with Streptavidin なばに 
Cy5 (ebioscience) diluted 1:2000 in 5% BSA for 15 minutes. After a final wash なばぬ 
with PBST followed by distilled water, slides were dried by centrifugation at 500 g なばね 
for 4 minutes. Unless stated otherwise, all wash steps were carried out at RT with なばの 
shaking. Slides were scanned using a GenePix 4200AL scanner, a PMT of 450 なばは 
and 100% power. The resultant TIFF images were processed with Axon Genepix なばば 
Pro-6 Microarray Image Analysis software (Molecular Services Inc.) to obtain なばぱ 
fluorescence data for each feature and generate gpr files. Protein signals were なばひ 
finally determined with background subtraction using RPPanalyzer, a module なぱど 
within the R statistical language on the CRAN (http://cran.r-project.org/) [33] なぱな 
 なぱに 
Statistical analysis なぱぬ 
 ひ
Antibody levels were calculated using GraphPad Prism 6.0 Software. As data なぱね 
collected for antibody measurements were not normally distributed, non-なぱの 
parametric tests were employed with medians and ranges calculated. For なぱは 
comparison of multiple groups, Kruskall Wallis one-way ANOVA was used with なぱば 
Dunn’s post-test. Correlation was evaluated using the Spearman rank correlation なぱぱ 
coefficient test.  P values of <0.05 were considered to represent  statistically なぱひ 
significant differences. なひど 
 なひな 
Results なひに 
Quality control measures なひぬ 
Internal QC measures on each array were devised to support inter-assay なひね 
normalization, assay performance and data acquisition machine performance なひの 
monitoring. These measures included the addition of a replicated serial dilution of なひは 
human IgG to verify function of the detection system and provide a standard なひば 
curve of human IgG against which antibody responses could be calibrated. なひぱ 
Antigens from 2 known human pathogens (tetanus toxoid and Candida albicans), なひひ 
where the majority of normal individuals would be expected to have some にどど 
existing protective antibody response were incorporated onto each array. These にどな 
positive control antigens were examined for each array as an indicator of sample にどに 
integrity. Figure 1 shows a plot of the responses seen in 327 serum samples for にどぬ 
each of the 2 control antigens. Strong responses are seen to tetanus toxoid and にどね 
Candida albicans. Negative controls were also incorporated onto each array as a にどの 
further internal QC measure. にどは 
 など
 にどば 
Microarray Intra- and Inter-assay Precision にどぱ 
 にどひ 
Microarray intra-and inter-assay variability was calculated using the sera of 7 になど 
patients. Identical samples were assayed on each of two slides at two になな 
independent time points. All antigens were spotted in replicates of five on each になに 
array. In the case of intra-assay variation, all 7 test and 2 control antigens fell になぬ 
within acceptable limits of precision [coefficient of variation (CV)  <10%; toxin A になね 
7.76%, toxin B 6.39%, SLP001 7.44%, SLP002 5.19%, SLP027 7.64%, TxA4 になの 
7.03%, TxB4 3.71%, tetanus 4.21%, candida 8.28%]. The inter-assay coefficient になは 
of variation for each antigen was calculated as 7.76%, 6.39%, 7.44%, 5.19%, になば 
7.64%, 7.03%, 3.71%, 4.21% and 8.26%, respectively.  になぱ 
 になひ 
Correlation between Microarray and ELISA assay results ににど 
 ににな 
Due to the lack of validated and commercially available quantitative and ににに 
standardized IgG ELISAs targeting toxins A and B or other C. difficile-associated ににぬ 
antigens, we compared specific IgG anti-toxin A and anti-toxin B antibody ににね 
measurements generated by microarray versus previously obtained in-house ににの 
indirect ELISA readings using the same patient test sera [21]. Spearman にには 
correlation coefficient was used to assess the level of agreement between the ににば 
two platforms and results are visually represented in Figure 2. When comparing ににぱ 
the microarray performance with the in-house ELISA assays, a good correlation ににひ 
 なな
coefficient was observed for toxin A (r= 0.7051; p<0.0001) with a moderately にぬど 
good correlation for toxin B (r= 0.5809 p<0.0001).  にぬな 
 にぬに 
Sensitivity and specificity にぬぬ 
Sensitivity and specificity of individual and panels of antibody response to C. にぬね 
difficile-specific antigens were calculated for both the CDI and CF groups using にぬの 
selected age-matched samples and the same panel of 7 antigens (Toxin A, Toxin にぬは 
B, SLP001, SLP002, SLP027, TxA4 and TxB4) based upon the same cut-off of にぬば 
95th percentile of the control samples. CF samples have a sensitivity and にぬぱ 
specificity of 75% and 100% respectively while the figures for CDI are 25% and にぬひ 
100% respectively. にねど 
 にねな 
Serum antibody reactivity profiles using microarray にねに 
 にねぬ 
A total of 327 serum samples were tested by microarray for the presence of にねね 
specific IgG antibody. The microarray assay was able to detect specific antibody にねの 
responses to all C. difficile antigens including recombinant toxin fragments tested にねは 
(example response to native antigens demonstrated in Figure 3). The signals にねば 
from positive control proteins (tetanus and candida) were similar in healthy にねぱ 
control individuals, patients with CF and CDI. Each array also included negative にねひ 
controls (buffer only and no serum or blank) which gave no signal. The reactivity にのど 
of these spots was routinely subtracted from all signals obtained from specific にのな 
antigens. The microarrays detected significantly higher levels of specific にのに 
 なに
antibodies in the CF group across all C. difficile antigens tested compared with にのぬ 
healthy control and with CDI sera (Figure 4). In the CDI group, antibody にのね 
responses to whole (Figure 4A and B) and recombinant toxins A and B (Figure 5) にのの 
did not differ compared with the healthy control group, but infected patients did にのは 
exhibit significantly lower anti-SLP IgG levels (all ribotypes) compared with にのば 
controls and with patients with CF (Figure 4C). No statistically significant にのぱ 
differences were observed in specific antibody levels to any of the antigens にのひ 





Current knowledge of the complete antigen repertoire recognized by patients にはの 
during CDI is sparse, limiting a detailed interrogation of immunity, exposure and にはは 
hindering preclinical vaccine development. The goal of this study was to develop, にはば 
validate and implement a novel protein microarray readout assay that allows the にはぱ 
accurate, precise, and reproducible quantification of specific antibody responses にはひ 
to a selected panel of C. difficile-specific microbial antigens using a pre-existing にばど 
bank of test sera.  にばな 
 にばに 
This study represents, to our knowledge, the first report of highly purified anti-にばぬ 
SLP 001, 002 and 027 IgG responses in a large cohort of patient sera and にばね 
extends the usefulness of immunoassay techniques through simultaneous にばの 
 なぬ
examination of multiple C. difficile-specific antigens including toxins in one にばは 
immunoassay layout. We demonstrate that serum C. difficile antigen-specific IgG にばば 
antibody responses can be detected using this technique, and that the magnitude にばぱ 
and breadth of response to individual specific microbial antigens differs greatly にばひ 
between individuals and patient groups.  にぱど 
 にぱな 
Whilst our assay achieved excellent specificity for the target panel of antigens にぱに 
analysed, lower detection sensitivity was observed, particularly for the CDI group. にぱぬ 
Importantly, antibody-based serological assays are hampered by the high にぱね 
likelihood or prior exposure to micro-organisms encountered in the environment.  にぱの 
In this regard, all populations previously exposed to C. difficile bacterial antigens にぱは 
will produce seropositive responses. Nevertheless, it should be possible to にぱば 
enhance sensitivity for specific antibody detection through probing the にぱぱ 
microarrays with a larger bank of longitudinal (acute and convalescent) test sera にぱひ 
and/or activated B lymphocyte supernatant samples which secrete antigen-にひど 
specific antibodies from patients with symptomatic CDI [21] and healthy controls にひな 
who do not carry C. difficile in their stool. In addition, detection sensitivity may be にひに 
improved by pooling several antigenic targets specific for C. difficile. にひぬ 
 にひね 
In contrast to previous studies asserting that development of symptomatic CDI にひの 
may be correlated with low IgG titres to toxin A but not to toxin B, our data do not にひは 
demonstrate any significant differences in IgG anti-toxin A or IgG anti-toxin B にひば 
levels in CDI patients compared to healthy controls. Similarly, other investigators にひぱ 
 なね
have either reported no disparities or higher serum anti-toxin A IgG levels in CDI にひひ 
patients compared to controls [11, 19, 34]. Although the carriage rate of C. ぬどど 
difficile in the control subjects was not known, the lack of difference may have ぬどな 
arisen due to the fact that most of the healthy control subjects in this study were ぬどに 
recruited from a pool of hospital and University co-workers. As such, it is likely ぬどぬ 
that natural asymptomatic exposure to toxigenic C. difficile was a more common ぬどね 
occurrence and thus may be due to transient colonization. Furthermore, we ぬどの 
acknowledge that patients in the CDI group were also older compared to ぬどは 
individuals in the CF and control groups. However, other investigators have ぬどば 
shown that serum antibody levels were not affected by age [13, 15].  It will be of ぬどぱ 
interest to determine whether specific qualitative and quantitative differences in T ぬどひ 
and B cell responses to C. difficile and its antigens account for higher prevalence ぬなど 
of CDI in older populations. ぬなな 
 ぬなに 
Notably, significantly higher anti-toxin and anti-SLP IgG antibody concentrations ぬなぬ 
in patients with CF (with no previous history of CDI) are likely to be due to more ぬなね 
frequent contact with the toxins and SLPs of C. difficile which occur with ぬなの 
colonization (especially after admission to hospital) and following antibiotic-ぬなは 
mediated disruption of the protective resident microflora. Indeed, two of the ぬなば 
patients with CF were asymptomatic carriers of C. difficile. Furthermore, this ぬなぱ 
particular small cohort of CF patients also had additional risk factors for C. ぬなひ 
difficile colonization/infection, including tube feeding (n=5), and the use of proton ぬにど 
pump inhibitors (n =14). ぬにな 
 なの
 ぬにに 
Whilst firm conclusions cannot be drawn because of the small number of subjects ぬにぬ 
studied, our present data suggest that the host’s ability to mount a robust ぬにね 
antibody response to multiple C. difficile-specific protein antigens as seen in the ぬにの 
CF group, may help confer protection from developing symptomatic CDI. ぬには 
Protection from symptomatic CDI may be a higher order phenomenon related to ぬにば 
patterns of antibody response as opposed to being attributable to any single ぬにぱ 
antigenic target. Notably, CDI is rarely seen in CF patients despite the presence ぬにひ 
of multiple risk factors for infection, including frequent exposures to antibiotics ぬぬど 
and hospitals. Several studies have also shown that patients with CF are often ぬぬな 
asymptomatic carriers of C. difficile [35-38] with one recent report indicating that ぬぬに 
most strains carried by CF patients were non-toxigenic (77% versus 17%) [38]. It ぬぬぬ 
is also possible that colonization with non-toxigenic C. difficile may protect ぬぬね 
against colonization with toxin-producing strains and/or that differences in colonic ぬぬの 
mucus or the microbiome may also contribute to protection in the CF population. ぬぬは 
Understanding the role of the gut microbiota in programming the immune ぬぬば 
phenotype in the context of CF may offer a series of interactive windows that ぬぬぱ 
could be aligned to prevent CDI. Further detailed studies that aim to dissect the ぬぬひ 
complex dialogue between the host, immune system and intestinal microbiota are ぬねど 
currently underway in a larger cohort of CF patients.  ぬねな 
 ぬねに 
Limitations of the present study are the small sample of strain-specific bacterial ぬねぬ 
proteins employed, unequal sample sizes in the different groups studies, lack of ぬねね 
 なは
age matching, the absence of colonizing/immunizing strain information, the study ぬねの 
of only one isotype, the lack of antibody neutralization data and the absence of ぬねは 
ELISA and microarray correlation data for the recombinant toxin fragments and ぬねば 
non-toxin antigens examined. Whether or not the immunogenicity of these latter ぬねぱ 
selected antigens contributes to CDI protection remains to be fully determined. ぬねひ 
We observed a lower correlation between microarray and ELISA in the toxin B ぬのど 
assays (r=0.58; P<0.0001). This finding was particularly apparent at increasing ぬのな 
IgG anti-toxin B concentrations and may mean that ELISA lacks accuracy at ぬのに 
higher specific anti-toxin B IgG concentrations. Discordance between both ぬのぬ 
methods could also be an effect of the low throughput of ELISA that requires the ぬのね 
samples to be analyzed in small batches over a longer period of time; by ぬのの 
contrast, the high-throughput array platforms permits analysis of large sample ぬのは 
cohorts under similar experimental conditions in a much more rapid time frame, ぬのば 
likely enhancing result reproducibility. Discrepancies between both technologies ぬのぱ 
may also have arisen due to variations in the quality of sera and toxins over time, ぬのひ 
especially when new batches/different sources of toxin were tested. These ぬはど 
results also suggest that mapping temporal changes in serological responses to ぬはな 
C. difficile may be best undertaken using high-throughput methods such as ぬはに 
protein microarray. ぬはぬ 
 ぬはね 
In summary, we verify that this initial design and implementation of a protein ぬはの 
microarray platform is well suited to identify, quantify and compare multiple ぬはは 
specific antigenic responses following challenge by C. difficile. Given that ぬはば 
 なば
antigenic variation occurs between different strains, host responses may well ぬはぱ 
vary according to which are the prevalent strains. High-throughput assays will be ぬはひ 
important in measuring the heterogeneity of host immune responses. ぬばど 
Modifications of this microarray approach could be employed to expand the ぬばな 
antigen targets to include proteins derived from multiple strains of C. difficile in ぬばに 
addition to investigating multiple isotype specificities. The microarray platform ぬばぬ 
could also be adapted to study cytokine/chemokine repertoires in response to ぬばね 
infection or vaccination for large collections of individual patient sera. Optimised ぬばの 
immunological marker panels are yet to be developed for predicting host ぬばは 
responses to C. difficile. Before advancements can be made, more detailed ぬばば 
careful studies in larger well defined prospective cohorts will be required before ぬばぱ 
this C. difficile antigen-specific microarray assay can be used as a prognostic tool ぬばひ 
as well as tailoring interventional strategies. Nevertheless, protein microarrays ぬぱど 
have the potential to provide a more comprehensive antigen-specific humoral ぬぱな 
immune response profile in vaccinated or infected humans, that could find ぬぱに 
beneficial applications in large-scale sero-epidemiological, longitudinal and sero-ぬぱぬ 
surveillance analyses ぬぱね 
 ぬぱの 
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Figure Legends.  のなぬ 
Figure 1. Testing sample integrity of all serum samples using two positive control のなね 
antigens: Tetanus toxoid and Candida albicans antigen. Strong responses are のなの 
seen to both antigens from all the samples. のなは 
Figure 2. Correlation between microarray and ELISA IgG anti-toxin A (A) and のなば 
IgG anti-toxin B (B) antibody levels in patients with C. difficile infection and in のなぱ 
patients with cystic fibrosis without a history of diarrhoea. Each dot represents a のなひ 
serum sample from an individual patient. Spearman correlation coefficient tests のにど 
revealed significant agreement between both assay results (*** denotes P < のにな 
0.0001). Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgG, のにに 
immunoglobulin G. のにぬ 
Figure 3. Selected serum IgG responses to C. difficile proteins on microarray. のにね 
Green (low) to red (high) signal intensity heat map representing the relative IgG のにの 
 にね
response to C. difficile immunoreactive antigens (native toxins A and B, and のには 
ribotype-specific surface layer proteins 001, 002, 027) in different serum samples のにば 
from patients infected with C. difficile, CF patients and healthy controls.  のにぱ 
Figure 4. Anti-toxin A (A) and anti-toxin B (B) IgG responses in healthy controls のにひ 
subjects and patients with C. difficile infection and a group of patients with cystic のぬど 
fibrosis and no history of diarrhoea. Differences between groups were calculated のぬな 
using the Kruskall-Wallis test followed by Dunn's post test for multiple のぬに 
comparisons. Horizontal lines in each graph represent the median. (C) Patients のぬぬ 
with cystic fibrosis had significantly higher levels of specific IgG antibody levels to のぬね 
toxins A and B compared to healthy controls and patients with C. difficile のぬの 
infection. In the microarray assays, there were significantly lower anti-SLP IgG のぬは 
levels across all ribotypes tested (001, 002, 027) in patients with C. difficile のぬば 
infection compared to patients with cystic fibrosis  and healthy controls (*** のぬぱ 
denotes p ≤0.001, ** denotes p ≤0.01, * denotes p ≤0.05). Abbreviations: SLP, のぬひ 
surface layer protein. のねど 
Figure 5. Anti-TxA4 and anti-TxB4 IgG responses in healthy controls, patients のねな 
with C. difficile infection and in a CF group of patients with no history of のねに 
diarrhoea. Differences between groups were calculated using the Kruskall-Wallis のねぬ 
test followed by Dunn's post test for multiple comparisons. Horizontal lines in のねね 
each graph represent the median. In the microarray assays, CF patients のねの 
displayed significantly higher IgG levels against both recombinant toxin のねは 
fragments compared to healthy controls and patients with C. difficile infection (*** のねば 
denotes p ≤0.001) . のねぱ 
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